See what’s new.
Evecxia Therapeutics Reports Favorable Data From a Phase 1 Single Ascending Dose Safety/Tolerability/PK/PD Trial of EVX-301
Evecxia Therapeutics is a Duke University start-up, founded by inventors Drs. Jacob Jacobsen and Marc Caron (Cell Biology, SOM) around their serotonin synthesis amplification therapeutic technology for mental health applications.
Four Points Innovation Funds Research Collaboration Between Duke University and The University of Manchester
This investment aims to accelerate research to develop a novel therapy to treat a genetic condition called Alport syndrome.
Donaldson Acquires Isolere Bio, Continuing to Build Life Sciences Business
“Isolere is thrilled to join the Donaldson family and bring our novel affinity-phase separation technology to market,” said Kelli Luginbuhl, Ph.D, co-founder and chief executive officer of Isolere.
Xilis and MD Anderson Announce Strategic Collaboration to Advance Novel Technology and Accelerate Therapeutic Development
Preclinical research agreement brings together Duke start-up Xilis' MicroOrganoSphere™ platform with MD Anderson's expertise in cancer research and therapeutic development.
Duke’s Aravind Asokan, Ph.D., named Global Scholar
As a Novartis Institute for Biomedical Research (NIBR) Global Scholar, Asokan will receive up to $1 million in funding over three years, along with "drug-hunting expertise from dedicated NIBR scientific collaborators" as part of this…
Istari Oncology Announces First Patient Dosed in the Non-Muscle-Invasive Bladder Cancer (NMIBC) Substudy of the LUMINOS-103 Basket Trial Evaluating Lerapolturev Monotherapy
Istari Oncology was founded by Drs. Darell Bigner and Matthias Gromeier (Neurosurgery, SOM).
FDA approves elacestrant for ER-positive, HER2-negative, ESR1-mutated advanced or metastatic breast cancer
Radius Health, with its eventual partner Stemline Therapeutics/Menarini Group, licensed the cancer indications for this drug in 2017 out of the lab of Dr. Donald McDonnell (Pharmacology and Cancer Biology, SOM).
Celebrating Major Milestones in Personalized Orthopaedics, restor3d Announces First Surgery Using the Next Generation Kinos Axiom® Total Ankle System Featuring TIDAL Technology™ and Launches Mobile Companion App of r3id Personalized Surgery Platform
restor3d, a leading medical device company that develops innovative technologies and manufactures 3D printed implants and instruments, celebrates two incredible company milestones. The first being the successful implantation of the next generation Kinos Axiom® Total Ankle…
PranaQ Secures $3M in Seed Funding
This post first appeared on the PranaQ website. PranaQ, a healthcare technology startup, successfully completed $3M in Seed round funding raising. The round was participated by multiple global venture capital firms, including DSC Investment, Smilegate Investment,…